Extraordinary General Meeting

The Board of Directors of Biotage has resolved to convene an extraordinary general meeting in order to adopt a resolution to authorize the Board of Directors to issue a total maximum of 20,000,000 new shares, or convertible debentures corresponding to such number of shares, with or without deviation from the shareholders preferential right, against payment in cash, through an issue in kind or through set-off, whereof not more than 10,000,000 new shares may be issued to others than the company’s shareholders. In connection with a directed issue against payment in cash, the subscription price for the new shares shall be determined in close connection with the share price for the Biotage share on Stockholmsbörsen (the Stockholm stock exchange) at the time of the new issue. In connection with an issue of convertible debentures, with deviation from the shareholders preferential right, against payment in cash, the subscription price as well as terms and condition for the debentures shall be on market terms. Issues may be made in order to secure repayment of the debt financing attributable to the acquisition of Argonaut. In case of full exercise of the authorization, the dilution effect amounts to around 28 per cent of the share capital and the votes. An extraordinary general meeting will be held on Tuesday 30 August, 2005 at 17 p.m. and notice convening the general meeting will be made public shortly. Contact: Jeff Bork, President and CEO Tel: +46 734 22 16 60, jeff.bork@biotage.se Tel+46 18 56 59 00 www.biotage.com